AOD-9604
A modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis without the diabetogenic or growth-promoting effects of full GH.
Also known as: Anti-Obesity Drug 9604, Advanced Obesity Drug, hGH Fragment 177-191, Tyr-hGH177-191
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
How It Works
AOD-9604 mimics the lipolytic region of human growth hormone. It stimulates the beta-3 adrenergic receptor pathway, enhancing fat breakdown while simultaneously inhibiting lipogenesis (new fat formation). Importantly, it does not affect blood sugar or IGF-1 levels, meaning it avoids the insulin resistance and proliferative risks associated with full-length GH. It has received GRAS (Generally Recognized As Safe) status from the FDA as a food additive, though its injectable form remains under different regulatory oversight.
Common Applications
Safety & Considerations
Clinical trials demonstrated a favorable safety profile with no significant adverse events. Does not affect glucose tolerance or promote cell proliferation. GRAS status supports its low toxicity. Limited long-term data for injectable use in humans. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.